☆ 4.8 Article

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

NATURE MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Review Virology

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies

Maryam Noori et al.

Summary: This study systematically reviewed 36 recent in vitro studies to evaluate the effectiveness of neutralizing antibodies induced by BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 variants. The results showed that the B.1.351 variant had the lowest sensitivity to neutralizing antibodies, while the B.1.1.7 variant had the highest sensitivity.

REVIEWS IN MEDICAL VIROLOGY (2022)

Add to Collection

Review Immunology

Mucosal vaccines - fortifying the frontiers

Ed C. Lavelle et al.

Summary: Mucosal vaccines have the potential to prevent infections and protect against disease development by inducing adaptive immunity at mucosal sites. However, most current mucosal vaccines consist of live attenuated and inactivated whole-cell preparations, and there is a need for safe and effective mucosal adjuvants and innovative antigen discovery and delivery strategies to advance these vaccines. Advancements in understanding innate and adaptive mucosal immunity, including mucosal antigen-presenting cells and resident memory cells, provide valuable insights to inform mucosal adjuvant design for pathogens like SARS-CoV-2 and cancer.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

Koen B. Pouwels et al.

Summary: This study in England found significant changes in the number of individuals testing positive for SARS-CoV-2 and risk factors for positivity over time from April to November 2020. Important risk factors for testing positive varied between the first and second waves, with age being a key driver of increased positivity rates in the second wave. Continued monitoring for SARS-CoV-2 in the community will be important for managing the COVID-19 pandemic moving forwards.

LANCET PUBLIC HEALTH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Patrick Tang et al.

Summary: mRNA COVID-19 vaccines demonstrate high effectiveness in preventing severe outcomes and death caused by the Delta variant in Qatar, despite lower effectiveness at blocking infection.

NATURE MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines

Joseph A. Lewnard et al.

Summary: Observational studies on COVID-19 vaccine effectiveness face challenges such as misclassification and confounding, which should be addressed through practical strategies at both study design and analysis stages to reduce bias. Traditional case-control and test-negative design studies may encounter important threats to validity, particularly in the context of SARS-CoV-2 infection and COVID-19 natural history parameters.

EPIDEMIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Madhumita Shrotri et al.

Summary: Single-dose vaccination with BNT162b2 and ChAdOx1 vaccines provides substantial protection against infection in older adults from 4-7 weeks after vaccination and might reduce SARS-CoV-2 transmission. However, the risk of infection is not eliminated, highlighting the ongoing need for non-pharmaceutical interventions to prevent transmission in long-term care facilities.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Hiam Chemaitelly et al.

Summary: A study showed that the mRNA-1273 vaccine is highly effective against the B.1.1.7 and B.1.351 variants of concern, with efficacy rates of 100% and 96.4% respectively. The vaccine's effectiveness increases rapidly in the weeks following the first dose, reaching maximum efficacy after the second dose, providing strong protection against severe COVID-19 outcomes.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Emma Pritchard et al.

Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.

NATURE MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Vaccine Effectiveness Studies in the Field

Stephen J. W. Evans et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimating epidemiologic dynamics from cross-sectional viral load distributions

James A. Hay et al.

Summary: Population distribution of viral loads changes during an epidemic, and Ct values from random samples can improve estimates of an epidemic's trajectory. Combining data from multiple samples enhances the precision and robustness of estimation. These methods can be applied to real-time estimates of epidemic trajectories for outbreak management and response.

SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

Hannah Chung et al.

Summary: The study demonstrates that two doses of mRNA covid-19 vaccines are highly effective against symptomatic infection and severe outcomes. However, the effectiveness of one dose is lower, particularly for older adults shortly after the first dose. For adults aged >=70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biology

Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time

A Sarah Walker et al.

eLife (2021)

Add to Collection

Article Microbiology

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Jia Wei et al.

Summary: A longitudinal study on 45,965 adults in the UK revealed that older individuals, especially those aged >60 years, had lower antibody levels after a single dose of ChAdOx1 or BNT162b2 COVID-19 vaccines. Prioritizing vaccine allocation for those not previously infected and older individuals for the second dose is recommended based on the findings. Further data is needed to fully understand the relationship between quantitative antibody responses and vaccine-mediated protection.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

Ahmed O. Hassan et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

Add to Collection

Review Immunology

Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.